

What do patients want and need to know when participating in clinical trials?

**Stanimir Hasurdjiev,** Executive Director European Liver Patients Association

### The Structure

- General Remarks
- Some data
- What would I like a CT to address and respect

### MY INVOLVEMENT IN CTS:



- European Liver Patients Association –
   Executive Director
- European Community Advisory Board (EATG) –
   Hepatitis Drugs Task-Force Leader
- Hepatitis Community Advisory Board, New York – European Representative
- Bulgarian National Patients` Organization -Chairperson

### THE ACTORS:



- Patients
- Doctors
- Industry
- Academics
- Investigators
- Ethics Committees
- Regulatory authorities

# Public Perceptions and Confidence in Clinical Research

**Ken Getz** 

Founder and Chairman, CISCRP, Senior Fellow, Tufts CSDD

W. Markatha Markatha

### PUBLIC CONFIDENCE AND TRUST IN THE CRE:




General Public Attitudes	Perceptions of Clinical Research Professionals		
70%-83% of Americans believe clinical research is 'very important' or 'essential' to advancing public health	42% of Americans and 36% of Europeans distrust biopharmaceutical companies		
65% of Europeans believe that clinical research plays an important role in advancing public health	31% of Americans believe the FDA is effective at ensuring public/patient safety		
	25% of Americans and 17% of Europeans believe that physicians and study staff are primarily motivated by greed		

Sources: Research! America (JAMA, 2005); Ohmann (2004); HarrisInteractive (2002, 2004, 2007)

# WHICH OF THESE INDUSTRIES DO YOU THINK ARE GENERALLY HONEST AND TRUSTWORTHY?:






### WHICH OF THESE INDUSTRIES DO



- Desperate (~29% believe only seriously-ill participate)
- Risk Takers (80% believe participants are 'gambling' with their health)
- Ambivalently respected (34% 'Don' t Admire' study volunteers)


### Who makes a better contribution to mankind?



### INTERNATIONAL VOLUNTEERISM RATES



Percent of Population Ever' Participated



Sources: HarrisInteractive, 2005

# PREFERRED METHODS OF LEARNING ABOUT CLINICAL TRIALS



	US	W. Europe	UK	France	Germany	Italy	Spain
My Physician	51%	53%	40%	55%	58%	63%	52%
Email	28%	30%	34%	29%	30%	31%	27%
Media	21%	27%	17%	18%	25%	35%	30%
Advocacy Group	21%	21%	17%	18%	29%	15%	25%

Sources: HarrisInteractive, 2006

#### TAKEN FOR GRANTED



- I want simple explanation of the research question
- I need adequate time and space to review the trial and consider participation
- What are all my options with existing interventions
- What are the risks
- Protections and insurance is in place
- Confidentiality of my data

#### WHAT DO I WANT?



- Find out about trials
- Review by patient group
- Be informed of due process
- Who can I ask about what is presented to me?
- Other research on the same condition?
- How many people and for how long have been tested with this new interventions/drug

#### WHAT DO I WANT?



- Is there something better coming in the near future and can I wait for it?
- When and how will I get the results of the trial?
- Is this trial addressing everybody?
- Will there be a follow up?
- Is my time respected?

### **EXAMPLE: HEPATITIS C TREATMENT**



- IFN/RBV
- INF/RBV+TPV or BOC
- INF/RBV+ other DAAs
- INF-free combinations

Resistance, duration, tolerability, success rates, compliance, disease progression?



 How many patients have the expertise to find and understand the answers of all these question before making a decision to enter a CT?

 How many CTs are designed and planned to meet these expectations of the patients?

## ROLE OF PATIENTS' ORGANIZATIONS' AND PATIENT EXPERTS



- Involvement in Drug Development & Clinical Trials Designs
- Increased institutional involvement in Regulatory agencies
- Scientific Societies, Conferences & Guidelines,
   Research Advisory Boards
- Involvement in the recruitment process



 How many Patients Organisations are prepared to be involved in CTs?

Do we have enough Patients Experts?

### What is EUPATI?










The EUPATI project receives support from the European Union (IMI JU) and EFPIA companies

# WHAT IS THE EUROPEAN PATIENTS ACADEMY ON THERAPEUTIC INNOVATION?



The European Patients' Academy on Therapeutic Innovation is:

- initiated and led by key European Patient Advocacy organizations
- the key European initiative that will develop and provide objective, credible, correct and up-to-date public knowledge about medical research
- a paradigm shift in empowering patients and the public to understand medical research and how to contribute to it
- a **strong multi-stakeholder consortium** of patient organizations, academia, NGOs and industry



#### THANK YOU FOR THE ATTENTION

AN MONTH OF THE MAN STANDER WAS AND A STANDARD OF THE STANDARD